CSL Behring Announces Discontinuation of Mononine Coagulation Factor IX

CSL Behring issued the following statement to patient advocacy groups: “CSL Behring is focused on delivering breakthrough therapies to improve patients’ lives and meet the changing needs of our patients. Since CSL Behring’s introduction of MONONINE® Coagulation Factor IX (Human) in 1992, advancements have been made for the treatment of Hemophilia B.  Over time, patients […]

en_USEnglish